Fenoldopam: A new parenteral antihypertensive: Consensus roundtable on the management of perioperative hypertension and hypertensive crises

Suzanne Oparil, Solomon Aronson, G. Michael Deeb, Murray Epstein, Jerrold H. Levy, Robert R. Luther, Richard Prielipp, Addison Taylor

Research output: Contribution to journalReview articlepeer-review

51 Scopus citations

Abstract

A panel of clinicians from anesthesiology, surgery, nephrology, hypertension, cardiology, and pharmacology was convened to discuss pharmacologic therapeutics in the management of hypertensive crisis and perioperative hypertension. The panel discussed the advantages and limitations of currently available parenteral drugs, and assessed the potential use of fenoldopam mesylate, a drug in clinical development since 1981, and recently approved by the U.S. Food and Drug Administration (FDA). Fenoldopam is a dopamine receptor (DA1 selective) agonist that is a systemic and renal vasodilator. It was concluded that fenoldopam offers significant advantages as a parenterally administered agent for the management of blood pressure in both hypertensive emergencies and in the perioperative setting.

Original languageEnglish (US)
Pages (from-to)653-664
Number of pages12
JournalAmerican journal of hypertension
Volume12
Issue number7
DOIs
StatePublished - Jul 1999

Keywords

  • Fenoldopam mesylate
  • Hypertension
  • Hypertensive crisis
  • Perioperative hypertension

Fingerprint

Dive into the research topics of 'Fenoldopam: A new parenteral antihypertensive: Consensus roundtable on the management of perioperative hypertension and hypertensive crises'. Together they form a unique fingerprint.

Cite this